{
    "clinical_study": {
        "@rank": "144537", 
        "acronym": "VeClose", 
        "arm_group": [
            {
                "arm_group_label": "VenaSeal Sapheon Closure System", 
                "arm_group_type": "Experimental", 
                "description": "Designed to facilitate embolization with coaptation of lower extremity veins, including the GSV, in patients with venous reflux disease."
            }, 
            {
                "arm_group_label": "ClosureFast Radiofrequency Ablation", 
                "arm_group_type": "Active Comparator", 
                "description": "Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized control trial comparing VenaSeal Sapheon Closure System with\n      Radiofrequency Ablation."
        }, 
        "brief_title": "VenaSeal Sapheon Closure System Pivotal Study", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Great Saphenous Vein (GSV) With Venous Reflux Disease", 
        "detailed_description": {
            "textblock": "To demonstrate safety and effectiveness of the VenaSeal SCS as being both non-inferior to RF\n      ablation therapy in achieving anatomical closure of lower extremity superficial truncal\n      veins in patients with venous reflux through endovascular transcatheter embolization with\n      coaptation of the great saphenous vein (GSV) and in the reduction of intraprocedural and\n      post procedural pain and symptoms. The study will demonstrate safety of the VenaSeal SCS by\n      follow-up visits that will evaluate via duplex ultrasound and physical exam the presence of\n      deep vein thrombosis and or pulmonary embolus."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u226521 years and \u2264 70 years of age at the time of screening\n\n          2. Reflux in the great saphenous vein (GSV) greater than 0.5 sec reflux\n\n          3. One or more of the following symptoms related to the target vein: aching, throbbing,\n             heaviness, fatigue, pruritis, night cramps, restlessness, generalized pain or\n             discomfort, swelling\n\n          4. GSV diameter while standing of 3-12 mm throughout the target vein as measured by\n             Duplex ultrasound.\n\n          5. CEAP classification of C2 (if symptomatic) - C4b\n\n          6. Ability to walk unassisted\n\n          7. Ability to attend follow-up visits\n\n          8. Ability to understand the requirements of the study and to provide informed consent.\n\n        Exclusion Criteria:\n\n          1. Life expectancy < 1 year\n\n          2. Active treatment for malignancy other than non-melanoma skin cancer\n\n          3. Symptomatic peripheral arterial disease with ABI <0.89\n\n          4. Daily use of narcotic or non-steroidal anti-inflammatory pain medications to control\n             pain associated with GSV reflux.\n\n          5. Current, regular use of systemic anticoagulation (e.g., warfarin, heparin)\n\n          6. Previous or suspected deep vein thrombosis (DVT) or pulmonary embolus (PE).\n\n          7. Previous superficial thrombophlebitis in GSV.\n\n          8. Previous treatment of venous disease in target limb, other than spider vein\n             treatment.\n\n          9. Known hypercoagulable disorder.\n\n         10. Conditions which prevent vein treatment\n\n         11. Immobilization or inability to ambulate\n\n         12. Pregnant prior to enrollment\n\n         13. Tortuous GSV, which, in the opinion of the investigator, will limit catheter\n             placement or require more than one primary access site.\n\n         14. Aneurysm of the target vein with local diameter >12 mm\n\n         15. Significant, incompetent, ipsilateral small saphenous, intersaphenous or anterior\n             accessory great saphenous vein(s).\n\n         16. Known sensitivity to cyanoacrylate (CA) adhesives.\n\n         17. Current participation in another clinical study involving an investigational agent or\n             treatment, or within the 30 days prior to enrollment.\n\n         18. Patients who require bilateral treatment during the next 3 months\n\n         19. Patients who require additional ipsilateral treatments on the same leg within 3\n             months following treatment.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "244", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807585", 
            "org_study_id": "CP-11101-01"
        }, 
        "intervention": {
            "arm_group_label": [
                "VenaSeal Sapheon Closure System", 
                "ClosureFast Radiofrequency Ablation"
            ], 
            "intervention_name": "VenaSeal Sapheon Closure System (VSCS)", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "GSV", 
        "lastchanged_date": "September 13, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85255"
                    }, 
                    "name": "Morrison Vein Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92121"
                    }, 
                    "name": "GBK Cosmetic Laser Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenwood Village", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80111"
                    }, 
                    "name": "Radiology Imaging Associates (RIA)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakbrook Terrace; Suite 720", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60181"
                    }, 
                    "name": "Vein Clinics of America"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62701"
                    }, 
                    "name": "Prairie Education & Research Cooperative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hunt Valley", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21030"
                    }, 
                    "name": "MD Laser Skin & Vein Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Tonawanda", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14120"
                    }, 
                    "name": "Vein Institute of Buffalo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bend", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97701"
                    }, 
                    "name": "Inovia Vein Specialty Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Virginia Beach", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23452"
                    }, 
                    "name": "Sentara Vascular Specialist"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellevue", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98004-4623"
                    }, 
                    "name": "Lake Washington Vascular"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Control Trial Comparing VenaSeal Sapheon Closure System With Radiofrequency Ablation", 
        "overall_official": {
            "affiliation": "Morrison Vein Institute", 
            "last_name": "Nick Morrison, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the study is complete closure of the target vein where complete closure is defined as Doppler US showing vein closure along entire treated vein segment with no discrete segments of patency exceeding 5 cm as read by a qualified site technologist or investigator with independent reading by a Vascular Core Lab.", 
            "measure": "Complete closure of the target vein", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807585"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The subject will be asked to rate pain experienced during various aspects of the treatment procedure on a 0-10 numeric rating scale", 
                "measure": "Intraoperative pain", 
                "safety_issue": "Yes", 
                "time_frame": "During the procedure"
            }, 
            {
                "description": "The investigator will score the subjects ipsilateral leg ofr the occurrence of ecchymosis along treated segment", 
                "measure": "Ecchymosis at Day 3", 
                "safety_issue": "Yes", 
                "time_frame": "First follow up visit at day 3"
            }
        ], 
        "source": "Sapheon, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sapheon, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}